Esperion Therapeutics ESPR Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's operating lease liabilities (current)?
- Esperion Therapeutics (ESPR) reported operating lease liabilities (current) of $1.7M in Q1 2026.
- How has Esperion Therapeutics's operating lease liabilities (current) changed year-over-year?
- Esperion Therapeutics's operating lease liabilities (current) decreased by 39.8% year-over-year, from $2.82M to $1.7M.
- What is the long-term trend for Esperion Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Esperion Therapeutics's operating lease liabilities (current) has grown at a -4.1% compound annual growth rate (CAGR), from $2.59M to $2.1M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.